ADC Therapeutics SA (ADCT)

USD 1.44

(0.7%)

Net Income Summary of ADC Therapeutics SA

ADC Therapeutics SA's latest annual net income in 2023 was -240.05 Million USD , down -54.08% from previous year.
ADC Therapeutics SA's latest quarterly net income in 2024 Q2 was -36.54 Million USD , up 21.59% from previous quarter.
ADC Therapeutics SA reported an annual net income of -155.8 Million USD in 2022, up 32.27% from previous year.
ADC Therapeutics SA reported an annual net income of -230.02 Million USD in 2021, up 6.6% from previous year.
ADC Therapeutics SA reported a quarterly net income of -36.54 Million USD for 2024 Q2, up 21.59% from previous quarter.
ADC Therapeutics SA reported a quarterly net income of -47.11 Million USD for 2023 Q2, up 20.71% from previous quarter.

Annual Net Income Chart of ADC Therapeutics SA (2023 - 2017)

Historical Annual Net Income of ADC Therapeutics SA (2023 - 2017)

Year	Net Income	Net Income Growth
2023	-240.05 Million USD	-54.08%
2022	-155.8 Million USD	32.27%
2021	-230.02 Million USD	6.6%
2020	-246.29 Million USD	-111.44%
2019	-116.48 Million USD	5.37%
2018	-123.09 Million USD	-36.98%
2017	-89.86 Million USD	0.0%

Year	Net Income	Net Income Growth
2024 Q1	-46.6 Million USD	45.19%
2024 Q2	-36.54 Million USD	21.59%
2023 Q2	-47.11 Million USD	20.71%
2023 Q3	-47.8 Million USD	-1.46%
2023 Q1	-59.42 Million USD	-146.0%
2023 FY	-240.05 Million USD	-54.08%
2023 Q4	-85.03 Million USD	-77.86%
2022 Q4	-24.15 Million USD	52.27%
2022 Q3	-50.6 Million USD	21.38%
2022 Q2	-64.37 Million USD	-286.38%
2022 FY	-155.8 Million USD	32.27%
2022 Q1	-16.66 Million USD	51.54%
2021 FY	-230.02 Million USD	6.6%
2021 Q3	-71.54 Million USD	1.41%
2021 Q1	-51.52 Million USD	7.87%
2021 Q4	-34.38 Million USD	51.95%
2021 Q2	-72.56 Million USD	-40.84%
2020 Q1	-43.47 Million USD	-23.21%
2020 FY	-246.29 Million USD	-111.44%
2020 Q2	-126.55 Million USD	-191.1%
2020 Q3	-20.32 Million USD	83.94%
2020 Q4	-55.92 Million USD	-175.13%
2019 Q4	-35.28 Million USD	-12.58%
2019 Q3	-31.34 Million USD	-34.23%
2019 Q2	-23.34 Million USD	6.34%
2019 Q1	-24.92 Million USD	18.62%
2019 FY	-116.48 Million USD	5.37%
2018 Q3	-30.63 Million USD	0.91%
2018 Q2	-30.91 Million USD	0.0%
2018 FY	-123.09 Million USD	-36.98%
2018 Q1	-30.91 Million USD	0.0%
2018 Q4	-30.63 Million USD	0.0%
2017 FY	-89.86 Million USD	0.0%

Peer Net Income Comparison of ADC Therapeutics SA

Name	Net Income	Net Income Difference
Alto Neuroscience, Inc.	-36.3 Million USD	-561.212%
Annovis Bio, Inc.	-56.2 Million USD	-327.108%
Biohaven Pharmaceutical Holding Company Ltd.	-408.16 Million USD	41.188%
Ginkgo Bioworks Holdings, Inc.	-892.86 Million USD	73.114%
Nuvation Bio Inc.	-75.8 Million USD	-216.684%
Nuvation Bio Inc.	-75.8 Million USD	-216.684%
Arcus Biosciences, Inc.	-307 Million USD	21.807%
Zymeworks Inc.	-118.67 Million USD	-102.279%